Literature DB >> 19737531

Early growth response-1 is involved in foam cell formation and is upregulated by the TLR9-MyD88-ERK1/2 pathway.

Jin-Sik Kim1, Dae-Weon Park, Hyung-Kyoung Lee, Jae-Ryong Kim, Suk-Hwan Baek.   

Abstract

Early growth response-1 (Egr-1), a zinc finger transcription factor, plays a key regulatory role in pathological cardiovascular processes including atherosclerosis. Here, we investigate whether Egr-1 expression and foam cell formation require toll-like receptor 9 (TLR9) and myeloid differentiation factor 88 (MyD88). CpG DNA and its related synthetic CpG oligodeoxynucleotides (CpG ODN) play an important role in immunity and inflammation. CpG ODN increased expression of Egr-1 and formation of foam cells in Raw264.7 cells or bone marrow-derived macrophages. Egr-1 siRNA decreased foam cell formation by CpG ODN compared to that of control siRNA. In addition, when TLR9 or MyD88 was knocked down, CpG ODN-induced Egr-1 expression was also attenuated. CpG ODN increased ERK1/2 phosphorylation. U0126, a MEK pathway inhibitor, suppressed activation of Egr-1 expression by CpG ODN. CpG ODN-induced expression of tissue factor (TF) and NGFI-A binding protein 2 (Nab2), and the expression of both genes is blocked by knockdown of TLR9 or MyD88 siRNA or MEK inhibition. These results suggest that CpG ODN activates the TLR9-MyD88-ERK1/2 pathway causing expression of Egr-1 and its target genes such as TF and Nab2, thus inducing foam cell formation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19737531     DOI: 10.1016/j.bbrc.2009.09.009

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Toll-like Receptors in the Vascular System: Sensing the Dangers Within.

Authors:  Styliani Goulopoulou; Cameron G McCarthy; R Clinton Webb
Journal:  Pharmacol Rev       Date:  2016-01       Impact factor: 25.468

2.  CpG-ODN-mediated TLR9 innate immune signalling and calcium dyshomeostasis converge on the NFκB inhibitory protein IκBβ to drive IL1α and IL1β expression.

Authors:  Robyn De Dios; Leanna Nguyen; Sankar Ghosh; Sarah McKenna; Clyde J Wright
Journal:  Immunology       Date:  2020-03-18       Impact factor: 7.397

3.  Tissue factor, blood coagulation, and beyond: an overview.

Authors:  Arthur J Chu
Journal:  Int J Inflam       Date:  2011-09-20

4.  Toll-like receptor 9 signaling regulates tissue factor and tissue factor pathway inhibitor expression in human endothelial cells and coagulation in mice.

Authors:  Driss El Kebir; Anas Damlaj; Nesrine Makhezer; János G Filep
Journal:  Crit Care Med       Date:  2015-06       Impact factor: 7.598

5.  Pro-atherogenic actions of signal transducer and activator of transcription 1 serine 727 phosphorylation in LDL receptor deficient mice via modulation of plaque inflammation.

Authors:  Wijdan Al-Ahmadi; Thomas S Webberley; Alex Joseph; Ffion Harris; Yee-Hung Chan; Reem Alotibi; Jessica O Williams; Alaa Alahmadi; Thomas Decker; Timothy R Hughes; Dipak P Ramji
Journal:  FASEB J       Date:  2021-10       Impact factor: 5.834

6.  Equine herpesvirus type 1 infection induces procoagulant activity in equine monocytes.

Authors:  Wee Ming Yeo; Nikolaus Osterrieder; Tracy Stokol
Journal:  Vet Res       Date:  2013-03-11       Impact factor: 3.683

7.  Toll-Like Receptor 9 Inactivation Alleviated Atherosclerotic Progression and Inhibited Macrophage Polarized to M1 Phenotype in ApoE-/- Mice.

Authors:  Chunmei Ma; Qiufang Ouyang; Ziyang Huang; Xiaoqing Chen; Ye Lin; Weiping Hu; Ling Lin
Journal:  Dis Markers       Date:  2015-07-15       Impact factor: 3.434

8.  HIV-derived ssRNA binds to TLR8 to induce inflammation-driven macrophage foam cell formation.

Authors:  Mark A Bernard; Xinbing Han; Sonya Inderbitzin; Ifunanya Agbim; Hui Zhao; Henry Koziel; Souvenir D Tachado
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

9.  Valsartan independent of AT₁ receptor inhibits tissue factor, TLR-2 and -4 expression by regulation of Egr-1 through activation of AMPK in diabetic conditions.

Authors:  Yu Mi Ha; Eun Jung Park; Young Jin Kang; Sang Won Park; Hye Jung Kim; Ki Churl Chang
Journal:  J Cell Mol Med       Date:  2014-08-11       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.